Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Pugnière M[au]:

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. Ashraf Y et al. J Immunother Cancer. (2019)

PIP30/FAM192A is a novel regulator of the nuclear proteasome activator PA28γ. Jonik-Nowak B et al. Proc Natl Acad Sci U S A. (2018)

Cyclophilin A enables specific HIV-1 Tat palmitoylation and accumulation in uninfected cells. Chopard C et al. Nat Commun. (2018)

Search results

Items: 1 to 50 of 83

1.

Transportin-1 binds to the HIV-1 capsid via a nuclear localization signal and triggers uncoating.

Fernandez J, Machado AK, Lyonnais S, Chamontin C, Gärtner K, Léger T, Henriquet C, Garcia C, Portilho DM, Pugnière M, Chaloin L, Muriaux D, Yamauchi Y, Blaise M, Nisole S, Arhel NJ.

Nat Microbiol. 2019 Nov;4(11):1840-1850. doi: 10.1038/s41564-019-0575-6. Epub 2019 Oct 14.

PMID:
31611641
2.

CCSP counterbalances airway epithelial-driven neutrophilic chemotaxis.

Knabe L, Petit A, Vernisse C, Charriot J, Pugnière M, Henriquet C, Sasorith S, Molinari N, Chanez P, Berthet JP, Suehs C, Vachier I, Ahmed E, Bourdin A.

Eur Respir J. 2019 Jul 11;54(1). pii: 1802408. doi: 10.1183/13993003.02408-2018. Print 2019 Jul.

PMID:
31023848
3.

Targeting Aspergillus fumigatus Crf Transglycosylases With Neutralizing Antibody Is Relevant but Not Sufficient to Erase Fungal Burden in a Neutropenic Rat Model.

Chauvin D, Hust M, Schütte M, Chesnay A, Parent C, Moreira GMSG, Arroyo J, Sanz AB, Pugnière M, Martineau P, Chandenier J, Heuzé-Vourc'h N, Desoubeaux G.

Front Microbiol. 2019 Mar 26;10:600. doi: 10.3389/fmicb.2019.00600. eCollection 2019.

4.

Binding analysis between monomeric β-casein and hydrophobic bioactive compounds investigated by surface plasmon resonance and fluorescence spectroscopy.

Bahri A, Henriquet C, Pugnière M, Marchesseau S, Chevalier-Lucia D.

Food Chem. 2019 Jul 15;286:289-296. doi: 10.1016/j.foodchem.2019.01.176. Epub 2019 Feb 6.

PMID:
30827608
5.

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E.

J Immunother Cancer. 2019 Feb 4;7(1):29. doi: 10.1186/s40425-019-0498-z.

6.

A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.

Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnière M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Pèlegrin A, Poul MA.

MAbs. 2019 Apr;11(3):593-605. doi: 10.1080/19420862.2018.1564510. Epub 2019 Feb 18.

7.

Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.

Ogier C, Colombo PE, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C.

Cancer Lett. 2018 Sep 28;432:227-236. doi: 10.1016/j.canlet.2018.06.023. Epub 2018 Jun 20.

PMID:
29935372
8.

PIP30/FAM192A is a novel regulator of the nuclear proteasome activator PA28γ.

Jonik-Nowak B, Menneteau T, Fesquet D, Baldin V, Bonne-Andrea C, Méchali F, Fabre B, Boisguerin P, de Rossi S, Henriquet C, Pugnière M, Ducoux-Petit M, Burlet-Schiltz O, Lamond AI, Fort P, Boulon S, Bousquet MP, Coux O.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6477-E6486. doi: 10.1073/pnas.1722299115. Epub 2018 Jun 22.

9.

Cyclophilin A enables specific HIV-1 Tat palmitoylation and accumulation in uninfected cells.

Chopard C, Tong PBV, Tóth P, Schatz M, Yezid H, Debaisieux S, Mettling C, Gross A, Pugnière M, Tu A, Strub JM, Mesnard JM, Vitale N, Beaumelle B.

Nat Commun. 2018 Jun 8;9(1):2251. doi: 10.1038/s41467-018-04674-y.

10.

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.

Bougherara H, Némati F, Nicolas A, Massonnet G, Pugnière M, Ngô C, Le Frère-Belda MA, Leary A, Alexandre J, Meseure D, Barret JM, Navarro-Teulon I, Pèlegrin A, Roman-Roman S, Prost JF, Donnadieu E, Decaudin D.

Oncotarget. 2017 Oct 7;8(59):99950-99965. doi: 10.18632/oncotarget.21556. eCollection 2017 Nov 21.

11.

Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.

Courbet A, Bec N, Constant C, Larroque C, Pugniere M, El Messaoudi S, Zghaib Z, Khier S, Deleuze-Masquefa C, Gattacceca F.

PLoS One. 2017 Aug 10;12(8):e0182022. doi: 10.1371/journal.pone.0182022. eCollection 2017.

12.

Thrombospondin-1 (TSP-1), a new bone morphogenetic protein-2 and -4 (BMP-2/4) antagonist identified in pituitary cells.

Sallon C, Callebaut I, Boulay I, Fontaine J, Logeart-Avramoglou D, Henriquet C, Pugnière M, Cayla X, Monget P, Harichaux G, Labas V, Canepa S, Taragnat C.

J Biol Chem. 2017 Sep 15;292(37):15352-15368. doi: 10.1074/jbc.M116.736207. Epub 2017 Jul 26.

13.

Antibody targeting of claudin-1 as a potential colorectal cancer therapy.

Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M.

J Exp Clin Cancer Res. 2017 Jun 28;36(1):89. doi: 10.1186/s13046-017-0558-5.

14.

Atomic Force Microscopy Study of the Topography and Nanomechanics of Casein Micelles Captured by an Antibody.

Bahri A, Martin M, Gergely C, Pugnière M, Chevalier-Lucia D, Marchesseau S.

Langmuir. 2017 May 16;33(19):4720-4728. doi: 10.1021/acs.langmuir.7b00311. Epub 2017 May 8.

PMID:
28481103
15.

The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.

Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I.

Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715.

16.

Nanofluidic Fluorescence Microscopy (NFM) for real-time monitoring of protein binding kinetics and affinity studies.

Teerapanich P, Pugnière M, Henriquet C, Lin YL, Chou CF, Leïchlé T.

Biosens Bioelectron. 2017 Feb 15;88:25-33. doi: 10.1016/j.bios.2016.06.033. Epub 2016 Jul 30.

PMID:
27520501
17.

Developments in SPR Fragment Screening.

Chavanieu A, Pugnière M.

Expert Opin Drug Discov. 2016;11(5):489-99. doi: 10.1517/17460441.2016.1160888. Epub 2016 Mar 21. Review.

PMID:
26948323
18.

Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.

Golay J, Choblet S, Iwaszkiewicz J, Cérutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V, Michielin O, Berthou C, Kadouche J, Mach JP, Duonor-Cérutti M.

J Immunol. 2016 Apr 1;196(7):3199-211. doi: 10.4049/jimmunol.1501592. Epub 2016 Feb 26.

19.

Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro.

Brachet G, Respaud R, Arnoult C, Henriquet C, Dhommée C, Viaud-Massuard MC, Heuze-Vourc'h N, Joubert N, Pugnière M, Gouilleux-Gruart V.

Mol Pharm. 2016 Apr 4;13(4):1405-12. doi: 10.1021/acs.molpharmaceut.6b00082. Epub 2016 Mar 1.

PMID:
26900766
20.

IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.

Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, Watier H, Paintaud G, Gouilleux-Gruart V.

J Immunol. 2016 Jan 15;196(2):607-13. doi: 10.4049/jimmunol.1501780. Epub 2015 Dec 18.

21.

A method to confer Protein L binding ability to any antibody fragment.

Lakhrif Z, Pugnière M, Henriquet C, di Tommaso A, Dimier-Poisson I, Billiald P, Juste MO, Aubrey N.

MAbs. 2016;8(2):379-88. doi: 10.1080/19420862.2015.1116657. Epub 2015 Dec 18.

22.

Computational and biophysical approaches to protein-protein interaction inhibition of Plasmodium falciparum AMA1/RON2 complex.

Pihan E, Delgadillo RF, Tonkin ML, Pugnière M, Lebrun M, Boulanger MJ, Douguet D.

J Comput Aided Mol Des. 2015 Jun;29(6):525-39. doi: 10.1007/s10822-015-9842-7. Epub 2015 Mar 31.

PMID:
25822046
23.

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.

Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, Penault-Llorca F, Pasquet JM, Pèlegrin A, Robert B.

Oncogene. 2014 Nov 20;33(47):5405-14. doi: 10.1038/onc.2013.487. Epub 2013 Nov 18.

24.

Fragment-based identification of a locus in the Sec7 domain of Arno for the design of protein-protein interaction inhibitors.

Rouhana J, Hoh F, Estaran S, Henriquet C, Boublik Y, Kerkour A, Trouillard R, Martinez J, Pugnière M, Padilla A, Chavanieu A.

J Med Chem. 2013 Nov 14;56(21):8497-511. doi: 10.1021/jm4009357. Epub 2013 Oct 29.

PMID:
24112024
25.

Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T.

Neoplasia. 2013 Mar;15(3):335-47.

26.

Kinetics of interaction between ADP-ribosylation factor-1 (Arf1) and the Sec7 domain of Arno guanine nucleotide exchange factor, modulation by allosteric factors, and the uncompetitive inhibitor brefeldin A.

Rouhana J, Padilla A, Estaran S, Bakari S, Delbecq S, Boublik Y, Chopineau J, Pugnière M, Chavanieu A.

J Biol Chem. 2013 Feb 15;288(7):4659-72. doi: 10.1074/jbc.M112.391748. Epub 2012 Dec 19.

27.

Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity.

Ayrolles-Torro A, Imberdis T, Torrent J, Toupet K, Baskakov IV, Poncet-Montange G, Grégoire C, Roquet-Baneres F, Lehmann S, Rognan D, Pugnière M, Verdier JM, Perrier V.

J Neurosci. 2011 Oct 19;31(42):14882-92. doi: 10.1523/JNEUROSCI.0547-11.2011.

28.

Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide.

Tonkin ML, Roques M, Lamarque MH, Pugnière M, Douguet D, Crawford J, Lebrun M, Boulanger MJ.

Science. 2011 Jul 22;333(6041):463-7. doi: 10.1126/science.1204988.

29.

Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II.

Schmitt P, Wilmes M, Pugnière M, Aumelas A, Bachère E, Sahl HG, Schneider T, Destoumieux-Garzón D.

J Biol Chem. 2010 Sep 17;285(38):29208-16. doi: 10.1074/jbc.M110.143388. Epub 2010 Jul 6.

30.

Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells.

Rayne F, Debaisieux S, Yezid H, Lin YL, Mettling C, Konate K, Chazal N, Arold ST, Pugnière M, Sanchez F, Bonhoure A, Briant L, Loret E, Roy C, Beaumelle B.

EMBO J. 2010 Apr 21;29(8):1348-62. doi: 10.1038/emboj.2010.32. Epub 2010 Mar 11.

31.

Cyclophilin A as negative regulator of apoptosis by sequestering cytochrome c.

Bonfils C, Bec N, Larroque C, Del Rio M, Gongora C, Pugnière M, Martineau P.

Biochem Biophys Res Commun. 2010 Mar 5;393(2):325-30. doi: 10.1016/j.bbrc.2010.01.135. Epub 2010 Feb 6.

32.

Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen.

Behar G, Chames P, Teulon I, Cornillon A, Alshoukr F, Roquet F, Pugnière M, Teillaud JL, Gruaz-Guyon A, Pèlegrin A, Baty D.

FEBS J. 2009 Jul;276(14):3881-93. doi: 10.1111/j.1742-4658.2009.07101.x. Epub 2009 Jun 15.

33.

A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy.

Alvarez-Rueda N, Ladjemi MZ, Béhar G, Corgnac S, Pugnière M, Roquet F, Bascoul-Mollevi C, Baty D, Pèlegrin A, Navarro-Teulon I.

Vaccine. 2009 Jul 30;27(35):4826-33. doi: 10.1016/j.vaccine.2009.05.067. Epub 2009 Jun 11.

PMID:
19523913
34.

Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.

Banères-Roquet F, Gualtieri M, Villain-Guillot P, Pugnière M, Leonetti JP.

Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21.

35.

The antibiotics in the chemical space.

Gualtieri M, Banéres-Roquet F, Villain-Guillot P, Pugnière M, Leonetti JP.

Curr Med Chem. 2009;16(3):390-3. Review.

PMID:
19149585
36.

NMR structure of rALF-Pm3, an anti-lipopolysaccharide factor from shrimp: model of the possible lipid A-binding site.

Yang Y, Boze H, Chemardin P, Padilla A, Moulin G, Tassanakajon A, Pugnière M, Roquet F, Destoumieux-Garzón D, Gueguen Y, Bachère E, Aumelas A.

Biopolymers. 2009 Mar;91(3):207-20. doi: 10.1002/bip.21119.

PMID:
19107926
37.

A homogeneous resonance energy transfer-based assay to monitor MutS/DNA interactions.

Lopez-Crapez E, Malinge JM, Gatchitch F, Casano L, Langlois T, Pugnière M, Roquet F, Mathis G, Bazin H.

Anal Biochem. 2008 Dec 15;383(2):301-6. doi: 10.1016/j.ab.2008.09.004. Epub 2008 Sep 11.

PMID:
18824153
38.

Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells.

Behar G, Sibéril S, Groulet A, Chames P, Pugnière M, Boix C, Sautès-Fridman C, Teillaud JL, Baty D.

Protein Eng Des Sel. 2008 Jan;21(1):1-10. Epub 2007 Dec 11.

PMID:
18073223
39.

Evidence of a bactericidal permeability increasing protein in an invertebrate, the Crassostrea gigas Cg-BPI.

Gonzalez M, Gueguen Y, Destoumieux-Garzón D, Romestand B, Fievet J, Pugnière M, Roquet F, Escoubas JM, Vandenbulcke F, Levy O, Sauné L, Bulet P, Bachère E.

Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17759-64. Epub 2007 Oct 26.

40.

Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.

Villain-Guillot P, Gualtieri M, Bastide L, Roquet F, Martinez J, Amblard M, Pugniere M, Leonetti JP.

J Med Chem. 2007 Aug 23;50(17):4195-204. Epub 2007 Aug 1.

PMID:
17665895
41.

Antibody-antigenic peptide interactions monitored by SPR and QCM-D. A model for SPR detection of IA-2 autoantibodies in human serum.

Ayela C, Roquet F, Valera L, Granier C, Nicu L, Pugnière M.

Biosens Bioelectron. 2007 Jun 15;22(12):3113-9. Epub 2007 Feb 3.

PMID:
17349782
42.

Generation of llama single-domain antibodies against methotrexate, a prototypical hapten.

Alvarez-Rueda N, Behar G, Ferré V, Pugnière M, Roquet F, Gastinel L, Jacquot C, Aubry J, Baty D, Barbet J, Birklé S.

Mol Immunol. 2007 Mar;44(7):1680-90. Epub 2006 Sep 29.

PMID:
17011035
43.

Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.

Troadec S, Bès C, Chentouf M, Nguyen B, Briant L, Jacquet C, Chebli K, Pugnière M, Roquet F, Cerutti M, Chardès T.

Clin Immunol. 2006 Apr;119(1):38-50. Epub 2006 Jan 19.

PMID:
16426893
44.

HcPro, a multifunctional protein encoded by a plant RNA virus, targets the 20S proteasome and affects its enzymic activities.

Ballut L, Drucker M, Pugnière M, Cambon F, Blanc S, Roquet F, Candresse T, Schmid HP, Nicolas P, Gall OL, Badaoui S.

J Gen Virol. 2005 Sep;86(Pt 9):2595-603.

PMID:
16099919
45.

Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding.

Mechulam A, Cerutti M, Pugnière M, Missé D, Gajardo J, Roquet F, Robinson J, Veas F.

J Mol Med (Berl). 2005 Jul;83(7):542-52. Epub 2005 May 19.

PMID:
15905975
46.

Precise characterization of the epitope recognized by a monoclonal antibody against Escherichia coli RNA polymerase.

Andre E, Pugniere M, Latouche J, Granier C, Leonetti JP.

Hybridoma (Larchmt). 2005 Feb;24(1):1-5.

PMID:
15785203
47.

Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers.

Garambois V, Glaussel F, Foulquier E, Ychou M, Pugnière M, Luo RX, Bezabeh B, Pèlegrin A.

BMC Cancer. 2004 Oct 15;4:75.

48.

Changes in the dimeric state of neuronal nitric oxide synthase affect the kinetics of secretagogue-induced insulin response.

Lajoix AD, Pugnière M, Roquet F, Mani JC, Dietz S, Linck N, Faurie F, Ribes G, Petit P, Gross R.

Diabetes. 2004 Jun;53(6):1467-74.

49.

Directed mutagenesis in region 713-720 of human thyroperoxidase assigns 713KFPED717 residues as being involved in the B domain of the discontinuous immunodominant region recognized by human autoantibodies.

Bresson D, Pugnière M, Roquet F, Rebuffat SA, N-Guyen B, Cerutti M, Guo J, McLachlan SM, Rapoport B, Estienne V, Ruf J, Chardès T, Péraldi-Roux S.

J Biol Chem. 2004 Sep 10;279(37):39058-67. Epub 2004 May 18.

50.

Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice.

Coelho M, Gauthier P, Pugnière M, Roquet F, Pèlegrin A, Navarro-Teulon I.

Br J Cancer. 2004 May 17;90(10):2032-41.

Supplemental Content

Loading ...
Support Center